Effect of topical prostaglandin D2 on the aqueous humor dynamics in rabbits.
Effects of topically applied prostaglandin (PG) D2 on the aqueous outflow facility, uveoscleral flow, and aqueous flow rate were studied in rabbits to reveal its intraocular pressure (IOP)-reducing mechanism. The outflow facility after PGD2 application (50 micrograms) as measured by 2-min tonography was 0.19 microliters/min/mm Hg and did not differ from that before the application (0.22) or from that of the control contralateral eye (0.21). Direct measurement of the uveoscleral flow by perfusion of the anterior chamber for 30 min with fluorescein isothiocyanate-labeled dextran solution showed the flow rate to be about 0.15 microliters/min in indomethacin-treated (10 mg/kg, i.p.) rabbits. In these animals, PGD2 (50 micrograms) was ineffective in changing the flow rate, while PGF2 alpha (50 micrograms) significantly increased the flow by about 35%. Indirect assessment of the effects of PGs on this flow system was made using the uveoscleral flow-antagonizing ability of topical pilocarpine (1.5 mg). IOP reduction by PGD2 (50 micrograms) was only slightly inhibited by pilocarpine, while that by PGF2 alpha (10 micrograms) was markedly reduced. Aqueous flow rate measured fluorophotometrically was about 3.5 microliters/min in normal eyes. After PGD2 (50 micrograms) the flow rate was significantly reduced to 3.0 microliters/min. The magnitude of this reduction was estimated to be enough to account for the IOP reduction after application of 50 micrograms of PGD2. These results indicate that IOP reduction caused by topical PGD2 application is due mostly to the inhibition of aqueous flow rate.
Goh
Y
Y
Hayaishi Bioinformation Transfer Project, Research Development Corporation of Japan, Kyoto.
Araie
M
M
Nakajima
M
M
Azuma
I
I
Hayaishi
O
O
D000287:Administration, Topical; D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects* / Q000378:metabolism; D002924:Ciliary Body / Q000187:drug effects / Q000378:metabolism; D003911:Dextrans; D015237:Dinoprost / Q000494:pharmacology; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives*; D005452:Fluoresceins; D005470:Fluorometry; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D010862:Pilocarpine / Q000494:pharmacology; D011457:Prostaglandins D / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D012590:Sclera / Q000187:drug effects / Q000378:metabolism; D014065:Tonometry, Ocular; D014602:Uvea / Q000187:drug effects / Q000378:metabolism
D003911:Dextrans; D005452:Fluoresceins; D011457:Prostaglandins D; C015219:fluorescein isothiocyanate dextran; D010862:Pilocarpine; D015237:Dinoprost; D016650:Fluorescein-5-isothiocyanate